AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

22nd Century Group Inc

Change company Symbol lookup

Select an option...

XXII 22nd Century Group Inc

ALEC Alector Inc

BABA Alibaba Group Holding Ltd

JEQ abrdn Japan Equity Fund, Inc.

BAC Bank of America Corp

RVLWF Revitalist Lifestyle and Wellness Ltd

$NQUS45101010LMEURN Nasdaq US Brewers Large Mid Cap Net

$R25IG Russell 2500 Growth Index

TTC Toro Co

MPVDF Mountain Province Diamonds Inc

Consumer Staples : Tobacco | Small Cap Growth

Company profile

22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles, as well as improved yields and valuable agronomic traits. It has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits. The Company has an interest in RX Pharmatech Ltd (RXP).

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

4:33 pm ET November 21, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) rose 1.37% to $157.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.39% to 3,949.94 and Dow Jones Industrial Average falling 0.13% to 33,700.28. This was the stock's third consecutive day of gains. AbbVie Inc. closed $18.80 below its 52-week high ($175.91), which the company reached on April 8th.

The stock outperformed some of its competitors Monday, as Pfizer Inc. (PFE) fell 0.10% to $48.18, Eli Lilly & Co. (LLY) fell 0.14% to $361.17, and AstraZeneca PLC ADR (AZN.LN) rose 0.55% to $65.43. Trading volume (6.4 M) eclipsed its 50-day average volume of 5.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 21, 2022.

(END) Dow Jones Newswires

November 21, 2022 16:33 ET (21:33 GMT)